Galapagos wins possible €23.4 million from extended Genentech deal
This article was originally published in Scrip
Executive Summary
Roche’s Genentech has extended a drug discovery collaboration with Galapagos’ service division, Argenta, thereby prolonging the deal for another two years and increasing the potential value of the contract by £21.5 million (€23.4 million).